Breast Cancer

Chemotherapy advance reported for women with node-positive early breast cancer

Published in Health and Medicine Week, January 5th, 2004

A docetaxel (Taxotere)-based regimen reduced the relative risk of death in women with early stage breast cancer by 30% and lowered the relative risk of the cancer returning by 28% when compared to a standard adjuvant (postsurgery) regimen after 55-month follow-up.

The results of BCIRG 001, the first phase III study evaluating Taxotere after breast surgery, were presented at the San Antonio (Texas) Breast Cancer Symposium by the Breast Cancer International Research Group. .

"Taxotere continues to demonstrate its effectiveness across various stages of breast cancer, and this study indicates that women with early stage breast cancer and their physicians...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health and Medicine Week

Source: Health and Medicine Week (2004-01-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry